Last reviewed · How we verify
GSK1265744 Reference formulation
At a glance
| Generic name | GSK1265744 Reference formulation |
|---|---|
| Sponsor | ViiV Healthcare |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation (PHASE1)
- Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir (PHASE1)
- A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK1265744 Reference formulation CI brief — competitive landscape report
- GSK1265744 Reference formulation updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI